Acompanhe as Notícias da Recifes

For veterans with type 2 diabetes (T2D) receiving basal insulin therapy, the addition of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) does not increase the rate of insulin discontinuation compared with other glucose-lowering agents, according to a study published online

Drugs commonly used for weight loss, known as GLP-1 receptor agonists, have been found to reduce the key symptoms of binge eating disorder in a new review of evidence led by University College London (UCL) researchers.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as Ozempic or Wegovy, have revolutionized type 2 diabetes and weight-loss management, but they have also led to some unfortunate outcomes. A recent study in JAMA Psychiatry has raised concerns that GLP-1 medications may

According to new, independent research published in the Journal of the American Heart Association, GLP-1 receptor agonist (GLP-1 RA) medications reduce the number of deaths, amputations and hospitalizations among people with type 2 diabetes who also have narrowed leg arteries ass

For adults with type 2 diabetes mellitus (T2DM), bofanglutide, a glucagon-like peptide-1 receptor agonist, is associated with more meaningful reductions in hemoglobin A1C (HbA1c) levels than semaglutide, according to a study published online June 30 in the Annals of Internal Medi

GLP-1 agonists have become popular treatments for weight loss and type 2 diabetes, and newer studies suggest other health benefits as well. Findings from experiments on mice, published in the Journal of Virology, suggest that the drugs may offer benefits to another patient popula

A target trial emulation found that people with type 2 diabetes who started glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy had a slightly higher risk of ischemic optic neuropathy (ION), a rare condition involving reduced blood flow to the optic nerve that can cause su

Levantamento de VEJA SAÚDE quer mapear a percepção da população sobre as terapias disponíveis para perder peso e as tendências que devem chegar

Entenda a agonorexia, a ausência prolongada de fome causada por agonistas GLP-1, e como isso afeta a saúde mental O recorte ajuda a contextualizar a pauta dentro de Corrida.

Os medicamentos GLP-1 estão no centro de um debate acalorado após estudos apresentados no maior congresso de oncologia do mundo. Entenda o que realmente sabemos — e o que ainda é especulação.

Estudos da ASCO 2026 indicam que canetas emagrecedoras podem reduzir metástases em alguns cânceres, mas pesquisas ainda serão necessárias O post Além da balança: canetas emagrecedoras podem ajudar contra tumores apareceu primeiro em Olhar Digital.

Medicamentos da classe GLP-1, já usados no diabetes tipo 2 e na obesidade, foram associados a menos mortes, internações, revascularizações e amputações em pessoas com diabetes e doença arterial periférica.